BioPharma Dive
1,453 FOLLOWERS
BioPharma Dive is a leading industry publication providing in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing, and M&A to research partnerships.
BioPharma Dive
13h ago
All five large pharmaceutical companies to report earnings this week raised either their profit or revenue guidance for the year ..read more
BioPharma Dive
13h ago
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs ..read more
BioPharma Dive
17h ago
CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect ..read more
BioPharma Dive
17h ago
Some analysts described Sanofi’s pipeline of immune system therapies, which includes more than half a dozen drugs in mid- to late-stage testing, as “underappreciated” by investors, as sales of Dupixent rose over the last quarter ..read more
BioPharma Dive
17h ago
The Stop Corporate Capture Act would codify the Chevron doctrine, which required federal courts to give deference to agencies’ reasonable interpretation of ambiguous statutes ..read more
BioPharma Dive
17h ago
The drug’s advancement continued what one analyst described as a “torrid” pace for Viking’s closely watched medicine, which started human testing in 2022 and could reach a Phase 3 trial next year. ..read more
BioPharma Dive
2d ago
Known as SAGE-324, the drug was one of the key assets Biogen gained rights to through a billion-dollar research deal inked back in 2020 ..read more
BioPharma Dive
2d ago
While the study results were positive, questions remain about the longer-term potential of hemophilia treatments like Pfizer’s ..read more
BioPharma Dive
2d ago
Top executives at CVS Caremark, Optum Rx and Express Scripts made a rare congressional appearance to defend their companies’ drug pricing policies ..read more
BioPharma Dive
2d ago
Michelle Tarver, deputy director for transformation, will serve as acting director of the FDA’s medical devices office ..read more